CIK 0001108205 · Non-accelerated filer<br>Smaller reporting company
CURIS INC
Sign in to watch- Ticker
- CRIS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043505116
- Phone
- 617-503-6500
- Business address
- 128 SPRING STREET, BUILDING C, SUITE 500, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-03-02 | Dentzer James E President & CEO | Grant or award · Employee stock option (right to buy) | +750,000 | 750,000 | ||
| 2020-01-24 | Dentzer James E President & CEO | Sale | −3,094 | $1.64 | $5K | 42,158 |
| 2020-01-23 | Dentzer James E President & CEO | Sale | −3,658 | $1.69 | $6K | 45,252 |
| 2019-09-10 | Steinkrauss William Chief Financial Officer | Grant or award · Employee stock option (right to buy) | +125,000 | 125,000 | ||
| 2019-05-23 | Dentzer James E President & CEO | Grant or award · Employee stock option (right to buy) | +1,115,871 | 1,115,871 | ||
| 2019-05-23 | Martell Robert Head of Research & Development | Grant or award · Employee stock option (right to buy) | +386,996 | 386,996 | ||
| 2019-01-24 | Dentzer James E President & CEO | Sale | −3,094 | $1.16 | $4K | 41,639 |
| 2019-01-23 | Dentzer James E President & CEO | Sale | −2,397 | $1.09 | $3K | 44,733 |
| 2019-01-23 | Martell Robert Head of Research & Development | Shares withheld for taxes | −8,473 | $1.07 | $9K | 28,527 |
| 2019-01-23 | Martell Robert Head of Research & Development | Sale | −5,500 | $1.07 | $6K | 23,027 |
| 2019-01-23 | GREENACRE MARTYN D Director | Sale | −18,500 | $1.05 | $19K | 26,089 |
| 2019-01-23 | Rubin Marc Director | Sale | −18,500 | $1.05 | $19K | 28,819 |
| 2019-01-23 | Kunkel Lori Anne Director | Sale | −14,800 | $1.05 | $16K | 22,200 |
| 2019-01-23 | KAITIN KENNETH I Director | Sale | −14,800 | $1.05 | $16K | 28,121 |
| 2019-01-21 | GREENACRE MARTYN D Director | Grant or award · Non Qualified Stock Option | +180,000 | 180,000 | ||
| 2019-01-21 | KAITIN KENNETH I Director | Grant or award · Non Qualified Stock Option | +180,000 | 180,000 | ||
| 2019-01-21 | Rubin Marc Director | Grant or award · Non Qualified Stock Option | +180,000 | 180,000 | ||
| 2019-01-21 | Kunkel Lori Anne Director | Grant or award · Non Qualified Stock Option | +180,000 | 180,000 | ||
| 2018-09-26 | Dentzer James E President & CEO | Grant or award · Employee stock option (right to buy) | +750,000 | 750,000 | ||
| 2018-06-01 | Martell Robert Head of Research & Development | Grant or award · Employee stock option (right to buy) | +303,000 | 303,000 |
Page 6 of 17 · 326 trades